vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and AlTi Global, Inc. (ALTI). Click either name above to swap in a different company.
ADMA BIOLOGICS, INC. is the larger business by last-quarter revenue ($139.2M vs $86.6M, roughly 1.6× AlTi Global, Inc.). ADMA BIOLOGICS, INC. runs the higher net margin — 35.5% vs -15.1%, a 50.6% gap on every dollar of revenue. On growth, AlTi Global, Inc. posted the faster year-over-year revenue change (87.0% vs 18.4%). ADMA BIOLOGICS, INC. produced more free cash flow last quarter ($34.6M vs $-52.2M). Over the past eight quarters, AlTi Global, Inc.'s revenue compounded faster (30.6% CAGR vs 30.4%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
Cristal Global is the world's second-largest producer of titanium dioxide and a leading producer of titanium chemicals. It was formed when The National Titanium Dioxide Company Ltd. combined with Millennium Chemicals. The headquarters are in Jeddah, Saudi Arabia. It is a significant shareholder in Bemax, the world’s 5th largest TiO2 feedstock producer.
ADMA vs ALTI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $86.6M |
| Net Profit | $49.4M | $-13.1M |
| Gross Margin | 63.8% | — |
| Operating Margin | 45.1% | -2.1% |
| Net Margin | 35.5% | -15.1% |
| Revenue YoY | 18.4% | 87.0% |
| Net Profit YoY | -55.9% | 75.6% |
| EPS (diluted) | $0.20 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $139.2M | $86.6M | ||
| Q3 25 | $134.2M | $57.2M | ||
| Q2 25 | $122.0M | $53.1M | ||
| Q1 25 | $114.8M | $58.0M | ||
| Q4 24 | $117.5M | $46.3M | ||
| Q3 24 | $119.8M | $51.8M | ||
| Q2 24 | $107.2M | $49.5M | ||
| Q1 24 | $81.9M | $50.8M |
| Q4 25 | $49.4M | $-13.1M | ||
| Q3 25 | $36.4M | $-84.1M | ||
| Q2 25 | $34.2M | $-24.4M | ||
| Q1 25 | $26.9M | $1.9M | ||
| Q4 24 | $111.9M | $-53.8M | ||
| Q3 24 | $35.9M | $-72.5M | ||
| Q2 24 | $32.1M | $-6.4M | ||
| Q1 24 | $17.8M | $29.7M |
| Q4 25 | 63.8% | — | ||
| Q3 25 | 56.3% | — | ||
| Q2 25 | 55.1% | — | ||
| Q1 25 | 53.2% | — | ||
| Q4 24 | 53.9% | — | ||
| Q3 24 | 49.8% | — | ||
| Q2 24 | 53.6% | — | ||
| Q1 24 | 47.8% | — |
| Q4 25 | 45.1% | -2.1% | ||
| Q3 25 | 38.0% | -49.8% | ||
| Q2 25 | 35.1% | -56.7% | ||
| Q1 25 | 30.4% | -23.3% | ||
| Q4 24 | 32.6% | -42.7% | ||
| Q3 24 | 33.1% | -18.4% | ||
| Q2 24 | 36.6% | -30.2% | ||
| Q1 24 | 26.7% | -28.9% |
| Q4 25 | 35.5% | -15.1% | ||
| Q3 25 | 27.1% | -147.0% | ||
| Q2 25 | 28.1% | -45.9% | ||
| Q1 25 | 23.4% | 3.3% | ||
| Q4 24 | 95.2% | -116.1% | ||
| Q3 24 | 30.0% | -140.0% | ||
| Q2 24 | 29.9% | -12.9% | ||
| Q1 24 | 21.7% | 58.4% |
| Q4 25 | $0.20 | — | ||
| Q3 25 | $0.15 | — | ||
| Q2 25 | $0.14 | $-0.33 | ||
| Q1 25 | $0.11 | $-0.04 | ||
| Q4 24 | $0.45 | $-0.71 | ||
| Q3 24 | $0.15 | $-0.88 | ||
| Q2 24 | $0.13 | $-0.18 | ||
| Q1 24 | $0.08 | $0.18 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | $41.2M |
| Total DebtLower is stronger | $72.1M | $883.0K |
| Stockholders' EquityBook value | $477.3M | $600.1M |
| Total Assets | $624.2M | $1.2B |
| Debt / EquityLower = less leverage | 0.15× | 0.00× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $87.6M | $41.2M | ||
| Q3 25 | $61.4M | $35.8M | ||
| Q2 25 | $90.3M | $42.4M | ||
| Q1 25 | $71.6M | $52.8M | ||
| Q4 24 | $103.1M | $64.4M | ||
| Q3 24 | $86.7M | $220.6M | ||
| Q2 24 | $88.2M | $60.0M | ||
| Q1 24 | $45.3M | $134.2M |
| Q4 25 | $72.1M | $883.0K | ||
| Q3 25 | $72.4M | $586.0K | ||
| Q2 25 | — | $673.0K | ||
| Q1 25 | — | — | ||
| Q4 24 | $72.3M | $0 | ||
| Q3 24 | — | $128.4M | ||
| Q2 24 | — | $164.0M | ||
| Q1 24 | — | $183.7M |
| Q4 25 | $477.3M | $600.1M | ||
| Q3 25 | $431.2M | $607.2M | ||
| Q2 25 | $398.3M | $685.4M | ||
| Q1 25 | $373.4M | $665.2M | ||
| Q4 24 | $349.0M | $658.4M | ||
| Q3 24 | $231.9M | $707.0M | ||
| Q2 24 | $188.3M | $540.2M | ||
| Q1 24 | $153.7M | $510.9M |
| Q4 25 | $624.2M | $1.2B | ||
| Q3 25 | $568.7M | $1.2B | ||
| Q2 25 | $558.4M | $1.2B | ||
| Q1 25 | $510.6M | $1.2B | ||
| Q4 24 | $488.7M | $1.3B | ||
| Q3 24 | $390.6M | $1.4B | ||
| Q2 24 | $376.4M | $1.3B | ||
| Q1 24 | $350.9M | $1.3B |
| Q4 25 | 0.15× | 0.00× | ||
| Q3 25 | 0.17× | 0.00× | ||
| Q2 25 | — | 0.00× | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | 0.00× | ||
| Q3 24 | — | 0.18× | ||
| Q2 24 | — | 0.30× | ||
| Q1 24 | — | 0.36× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | $-51.4M |
| Free Cash FlowOCF − Capex | $34.6M | $-52.2M |
| FCF MarginFCF / Revenue | 24.8% | -60.3% |
| Capex IntensityCapex / Revenue | 0.8% | 0.9% |
| Cash ConversionOCF / Net Profit | 0.72× | — |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.6M | $-51.4M | ||
| Q3 25 | $13.3M | $-53.5M | ||
| Q2 25 | $21.1M | $-19.9M | ||
| Q1 25 | $-19.7M | $-30.2M | ||
| Q4 24 | $50.2M | $-50.7M | ||
| Q3 24 | $25.0M | $-4.9M | ||
| Q2 24 | $45.6M | $-30.2M | ||
| Q1 24 | $-2.2M | $-15.5M |
| Q4 25 | $34.6M | $-52.2M | ||
| Q3 25 | $-1.1M | — | ||
| Q2 25 | $18.7M | $-20.0M | ||
| Q1 25 | $-24.4M | $-31.0M | ||
| Q4 24 | $47.5M | $-58.2M | ||
| Q3 24 | $24.0M | $-9.4M | ||
| Q2 24 | $43.6M | $-31.2M | ||
| Q1 24 | $-4.6M | $-15.7M |
| Q4 25 | 24.8% | -60.3% | ||
| Q3 25 | -0.8% | — | ||
| Q2 25 | 15.3% | -37.6% | ||
| Q1 25 | -21.2% | -53.4% | ||
| Q4 24 | 40.4% | -125.7% | ||
| Q3 24 | 20.0% | -18.2% | ||
| Q2 24 | 40.7% | -63.2% | ||
| Q1 24 | -5.6% | -30.9% |
| Q4 25 | 0.8% | 0.9% | ||
| Q3 25 | 10.7% | 0.0% | ||
| Q2 25 | 2.0% | 0.0% | ||
| Q1 25 | 4.1% | 1.3% | ||
| Q4 24 | 2.3% | 16.3% | ||
| Q3 24 | 0.9% | 8.7% | ||
| Q2 24 | 1.9% | 2.2% | ||
| Q1 24 | 2.9% | 0.4% |
| Q4 25 | 0.72× | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.62× | — | ||
| Q1 25 | -0.73× | -15.80× | ||
| Q4 24 | 0.45× | — | ||
| Q3 24 | 0.70× | — | ||
| Q2 24 | 1.42× | — | ||
| Q1 24 | -0.12× | -0.52× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
ALTI
| Management Advisory Fees | $51.1M | 59% |
| Other | $32.7M | 38% |
| Distributions From Investments | $2.9M | 3% |
